Representative Clients

Our clients are some of the world's most prestigious General and Limited Partners, who manage in excess of $500 billion. Sample clients include:


Bain Capital: http://www.baincapital.com: Established in 1984, Bain Capital is one of the world's leading private investment firms managing approximately $65 billion in assets under management. Our affiliated advisors make private equity, public equity, leveraged debt asset, venture capital, and absolute return investments across multiple sectors, industries, and asset classes. Since our inception, our competitive advantage has been grounded in a people-intensive, value-added investment approach that has enabled the firm to deliver industry-leading returns for our investors.


Hamilton Lane: http://www.hamiltonlane.com: Founded in 1991, Hamilton Lane is a global leader in private equity management. Hamilton Lane is a private, independent, employee-owned firm providing private equity investment management to investors around the world. With more than $15 billion of assets under management, plus an additional $86 billion in advisory assets, Hamilton Lane is one of the largest allocators of private equity capital in the world. Our firm manages capital exclusively in the private equity asset class through two main business lines:

• Customized strategies
o Separate accounts and advisory services
• Specialized products.
o Funds-of-funds, secondary funds, co-investment funds, Taft-Hartley funds and fund administration services.

Hamilton Lane is headquartered outside of Philadelphia, Pennsylvania and has offices throughout the U.S., Europe, and Asia. We have a global, sophisticated client base that includes public and corporate pension funds, sovereign wealth funds, Taft-Hartley funds, financial institutions, insurance companies, foundations, endowments and high net worth individuals. Our clients include a number of the world’s largest institutional investors, as well as many mid-sized and smaller institutions.


EMAlternatives: http://www.emalternatives.com: EMAlternatives is a private equity fund investor that focuses exclusively on global emerging markets.

EMAlternatives provides discretionary and non-discretionary services to sophisticated institutional investors seeking exposure to private equity outside traditional markets in North America and Western Europe. Through its single-account approach, EMAlternatives customizes its portfolio construction to address clients' existing relationships and unique preferences for geography and strategy.


MC Venture Partners: http://www.mcventurepartners.com/: The Principals of M/C Venture Partners have over two decades of private equity investing experience in emerging companies of all stages in communications, technology and media.

During this period, the firm has managed over $1.5 billion of institutional capital, generating returns in the top quartile for venture capital funds. The Firm is currently investing M/C Venture Partners VI, a $550 million growth equity fund raised in 2006 from the nation's largest state and corporate pension funds, prominent university endowments, private trusts, and strategic financial institutions..


Park Street Capital: http://www.parkstreetcapital.com: Park Street Capital L.L.C. is an independent, employee-owned investment management firm dedicated exclusively to investing in private market asset classes, including venture capital, private equity and natural resources.

Together with its predecessor organization, our firm has been making private partnership investments since 1997 using a disciplined and balanced approach that emphasizes thoughtful diversification across strategies, stages, industries and time. Park Street currently manages in excess of $2.8 billion in capital commitments on behalf of institutions and high net worth individuals through several fund-of-funds investment vehicles.


SV Life Sciences: http://www.svlifesciences.com: SV Life Sciences is a leading international life sciences venture capital firm. SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994. The SVLS team manages five venture capital funds and a publicly traded investment trust with approximately $2 billion of capital under management. The firm employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and health-care services. SVLS has offices in Boston, London and San Francisco.